

Disclosures

Personal Commercial (5)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Alleviant Medical	Research/Research Grants	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Axon Therapeutics	Research/Research Grants ‡ REBALANCE-HF (site PI)	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Corvia	Research/Research Grants ‡ REDUCE LAP-HF (site PI), REDUCE LAP-HF 2 (site PI), RESPONDER-HF (site PI)	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Novartis	Research/Research Grants	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Pfizer	Research/Research Grants ‡ ATTR-ACT, Tafamidis Extension Protocol, THAOS (registry); (site PI for all)	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (8)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
AHRQ	Research/Research Grants	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
American Heart Association	Research/Research Grants	Modest (< \$5,000)	Other
NIH/NHLBI	Research/Research Grants ‡ SPIRRIT-HFpEF (site PI)	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
NIH/NHLBI	Research/Research Grants ‡ TRANSFORM-HF (site PI)	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
NIH/NHLBI	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
NIH/NIA	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Veterans Health Administration	Research/Research Grants ‡ Cooperative Study #2025 (Study Chair)	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Veterans Health Administration	Research/Research Grants	Significant (>= \$5,000)	Prevention

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/20/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/20/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

On-Going Obligation Agreement | Signed on 9/20/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.